Scarica l'app Stockscreener
21.11
1.20%
0.25
Dopo l'orario di chiusura:
21.10
-0.010
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$20.86
Aprire:
$20.97
Volume 24 ore:
2.57M
Relative Volume:
1.64
Capitalizzazione di mercato:
$2.64B
Reddito:
$376.07M
Utile/perdita netta:
$-16.14M
Rapporto P/E:
-150.89
EPS:
-0.1399
Flusso di cassa netto:
$-16.31M
1 W Prestazione:
+8.26%
1M Prestazione:
-9.24%
6M Prestazione:
-31.82%
1 anno Prestazione:
+51.00%
Intervallo 1D:
$20.73
$21.34
Intervallo di 1 settimana:
$19.65
$21.41
Portata 52W:
$12.72
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
21.11 | 2.61B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
How (ARQT) Movements Inform Risk Allocation Models - Stock Traders Daily
Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock - Investing.com UK
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. By Investing.com - Investing.com Nigeria
Arcutis EVP, CMO Burnett sells $4,673 in common stock By Investing.com - Investing.com South Africa
Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting - Stock Titan
Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax - Stock Titan
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push By Investing.com - Investing.com Nigeria
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations - Investing.com Nigeria
State Street (NYSE: STT) holds 6.30M shares of Arcutis (5.1%) - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144: Patrick Burnett reports share dispositions - Stock Titan
Arcutis Biotherapeutics (ARQT) Form 144 lists 435 vested shares for resale - Stock Titan
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Arcutis Earnings Call Signals Momentum Amid Headwinds - TipRanks
FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC - Quantisnow
Arcutis outlines $480M-$495M 2026 revenue guidance while expanding ZORYVE sales teams - MSN
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion - Yahoo Finance
40 new Arcutis hires receive stock units and options under Nasdaq rule - Stock Titan
Prudential Financial (ARQT) reports 5.30M-share stake; Jennison holds 4.98M - Stock Titan
ARQT SEC FilingsArcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Arcutis Biotherapeutics (ARQT) Reports Strong Q1 2026 Earnings w - GuruFocus
ARQT Reiterates by Needham -- Price Target Maintained at $36.00 - GuruFocus
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36 - Moomoo
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis Biotherapeutics Reaffirmed at Buy as Growth Outlook Strengthens; $36 Price Target Maintained - TipRanks
Arcutis Biotherapeutics CMO sells $16,149 in shares By Investing.com - Investing.com Australia
Arcutis Biotherapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-05-07 - Seeking Alpha
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $31,661 in stock By Investing.com - Investing.com Australia
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com UK
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):